Condition: HR+/HER2+ Early Breast Cancer · Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
This prospective, response-adapted phase II study evaluates the efficacy and safety of neoadjuvant fovinaciclib in combination with aromatase inhibitors and dual HER2 blockade in patients with HR-positive/HER2-positive early breast cancer. All patients initially receive induction treatment with fovinaciclib plus endocrine therapy and HER2-targeted therapy, followed by early assessment of treatment response after 6 weeks of treatment. Patients demonstrating an adequate response continue the same regimen, whereas those with a suboptimal response are transitioned to standard neoadjuvant chemotherapy combined with HER2-targeted therapy prior to surgery. This adaptive approach aims to optimize treatment selection, improve therapeutic efficacy, and reduce unnecessary chemotherapy exposure.
This description comes directly from the study's public registry record.
Yunxiang Zhou · 15868131018 · yxzhou@zju.edu.cn
Always discuss trial participation with your own doctor first.
| The First Affiliated Hospital of Nanjing Medical University | Nanjing, Jiangsu, China | Recruiting |
| 2nd Affiliated Hospital, School of Medicine | Hangzhou, Zhejiang, China | Recruiting |
| Ningbo No. 2 Hospital | Ningbo, Zhejiang, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07616427